Glucotrack Announces IDE Submission for U.S. Clinical Study of its Novel Implantable Continuous ...

Glucotrack Announces IDE Submission for U.S. Clinical Study of its Novel Implantable Continuous ...

RUTHERFORD, N.J., May 07, 2026 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced that it has submitted…

Glucotrack seeks FDA approval for clinical study of CBGM technology

Glucotrack has submitted an IDE application to the US FDA, seeking approval to begin a clinical study in the US for its CBGM technology.The post Glucotrack seeks FDA approval for clinical study of CBGM technology appeared first on Medical Device Network.

Glucotrack submits long-term implantable CBGM for FDA IDE

Glucotrack 3-year continuous blood glucose monitor (CBGM) Glucotrack (Nasdaq:GCTK) announced today that it submitted its implantable continuous blood glucose monitor (CBGM) for FDA IDE. FDA IDE (investigational device exemption) would enable the company to initiate a U.S. clinical study for the fully implantable technology. Rutherford, New Jersey-based Glucotrack’s device features no on-body external component. The company aims to offer it for t…